Stock Fundamentals

Company Information

▼
Company Name
Nuvation Bio Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
ISIN: US67080N1019
CIK: 0001811063
CUSIP: 67080N101
Currency: USD
Full Time Employees: 298
Phone: 332 208 6102
Website: https://www.nuvationbio.com
Fiscal Year End: December
IPO Date: Aug 24, 2020
Description:

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Address:

1500 Broadway, New York, NY, United States, 10036

Directors & Officers

▼
Name Title Year Born
Dr. David T. Hung M.D. Founder, President, CEO & Chairman 1958
Dr. Gary Hattersley Ph.D. Chief Scientific Officer 1967
Ms. Colleen Sjogren Chief Commercial Officer 1971
Mr. Philippe Pierre Sauvage CFO & Principal Financial Officer 1977
Mr. Moses Makunje CPA VP of Finance and Principal Accounting & Financial Officer 1978
Dr. Stephen Dang Ph.D. Senior VP, General Counsel & Corporate Secretary NA
Ms. Stacy Markel Chief People Officer 1965
Dr. David C. Hanley Ph.D. Chief Technical Operations Officer 1970
Ms. Kerry A. Wentworth Chief Regulatory Officer 1973
Dr. David Liu M.D., Ph.D. Chief Medical Officer 1970

Shares Statistics

▼
Shares Outstanding: 346.60M
Shares Float: 234.81M
% Insiders: 1,878.70%
% Institutions: 6,221.10%
Short % Float: 21.78%

Valuation Metrics

▼
Enterprise Value: $1.05B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $1.52B
EBITDA: $-211.32M
Book Value: $0.88
Earnings/Share: $-0.60
Profit Margin: 0.00%
Operating Margin: -81.30%
ROA (TTM): -23.46%
ROE (TTM): -53.18%
Revenue (TTM): $62.90M
Revenue/Share (TTM): $0.18
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 633.10%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Download Financials (Excel)

Financial Charts

▼

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

Earnings History

▼

Balance Sheet (Yearly)

▼

Financial Ratios

▼
Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 6.95x 0.18x 0.49x -15.57x -0.29x
2024-12-31 9.04x 0.02x 0.14x -1,737.91x -0.01x
2023-12-31 44.11x 0.00x 0.03x N/A -0.03x
2022-12-31 50.70x 0.00x 0.03x -13.07x -0.01x
2021-12-31 45.62x 0.00x 0.04x -144.90x -0.01x
2020-12-31 33.69x 0.00x 0.03x N/A 0.00x
2019-12-31 37.42x 0.00x 0.03x N/A 0.00x
2018-12-31 0.18x -0.81x 5.71x N/A N/A

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 01, 2025 Dongfang Liu N/A Sale 150.00K $7.82 $1.17M
Nov 26, 2025 Dongfang Liu N/A Sale 10.00K $8.00 $80.00K
Nov 19, 2025 Dongfang Liu N/A Sale 15.00K $5.10 $76.50K
Nov 19, 2025 Dongfang Liu N/A Sale 15.00K $5.10 $76.50K
Nov 17, 2025 Dongfang Liu N/A Sale 15.00K $4.76 $71.40K
Nov 17, 2025 Dongfang Liu N/A Sale 15.00K $4.76 $71.40K
Oct 27, 2025 Gary Hattersley N/A Sale 100.00K $5.02 $502.00K
May 02, 2025 Dongfang Liu N/A Sale 20.00K $2.50 $50.00K
Apr 07, 2025 David Hung N/A Purchase 300.00K $1.62 $486.00K
Apr 04, 2025 David Hung N/A Purchase 200.00K $1.66 $332.00K

📦 Raw API Data (JSON Explorer)

▼

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about NUVB.US!